doi: 10.1056/NEJMra1615439 Summary Keywords diabetic peripheral neuropathy, glucagon-like peptide-1 receptor agonists, neuroprotection, inflammation, oxidative stress Citation Liu C, Wu T and Ren N (2024) Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
Assessment of thyroid carcinogenic risk and safety profile of GLP-1 receptor agonist semaglutide therapy for diabetes mellitus and obesity: a systematic literature review
The GLP-1 receptors may already be partially desensitized from semaglutide use, but the GIP receptors are "fresh" and fully responsive
People with a personal or family history of medullary thyroid cancer, or a condition called MEN2, should not take these drugs
Through telehealth, patients in Florida can receive complete evaluations and prescriptions without in-person visits